Clearmind Medicine announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office. The allowed claims are directed, among others to use a primary amine aminoindan compound to regulate binge behavior. This includes primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan, the company’s innovative psychedelic molecule. This latest patent builds upon Clearmind’s broad IP protection in the psychedelic space, which now includes 28 granted patents across 18 patent families, with patents granted in major jurisdictions such as the US, Europe, China, India, and now Hong Kong.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
- Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
- Clearmind Medicine signs patent licensing agreement with Yissum Research
- Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
- Clearmind Medicine advances MEAI-based alcohol substitute beverage program